Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
IACH 2021
At #SOHO2026, Gilles Salles of @MSKCancerCenter shared insights into a Phase I/II trial evaluating DS3790, a novel CD37-directed ADC for non-Hodgkin #lymphoma? 🚨
Find out more here:
🎥
#LYMsm #NonHodgkinLymphoma #CaxTx #CTSM #TrialUpdate
DS3790: phase I/II evaluation of a novel CD37-directed ADC in non-Hodgkin lymphoma
Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a first-in-human Phase I/II ...
ow.ly
As we approach the world's largest myeloma-specific conference, we want to take a moment to honor Professor Robert A. Kyle, known to many as the “Father of Myeloma.”
Prof. Kyle's scientific contributions have helped transform the diagnosis & treatment of #myeloma, and it was a
As September is #BloodCancerAwarenessMonth, we wanted to share our recent podcast on the diagnosis & management of hematologic malignancies during pregnancy ft. Daan Dierickx of @UZLeuven.🤰🩸
Learn about key factors guiding clinical decisions in pregnant patients and the
🎥 At #ESCCongress, Luuk Kieviet of @UMCU_Intl presented preliminary findings from a KOL survey evaluating heterogeneity in cardiac #amyloidosis care across Europe.
Watch the full interview here:
👉
#CardioOnc @escardio
Heterogeneity in cardiac amyloidosis care across Europe: insights from a KOL survey
Luuk Kieviet, MD, University Medical Center Utrecht, Utrecht, Netherlands, discusses preliminary findings from a key opi...
ow.ly
Fantastic conference chaired by @Daver_Leukemia and great session on menin inhibitors in which we are all excited about combination strategies and moving into frontline Tx. Thanks for inviting me to be part of this program #iwAL26
IACH 2021
At #SOHO2026, Gilles Salles of @MSKCancerCenter shared insights into a Phase I/II trial evaluating DS3790, a novel CD37-directed ADC for non-Hodgkin #lymphoma? 🚨
Find out more here:
🎥
#LYMsm #NonHodgkinLymphoma #CaxTx #CTSM #TrialUpdate
DS3790: phase I/II evaluation of a novel CD37-directed ADC in non-Hodgkin lymphoma
Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a first-in-human Phase I/II ...
ow.ly
As we approach the world's largest myeloma-specific conference, we want to take a moment to honor Professor Robert A. Kyle, known to many as the “Father of Myeloma.”
Prof. Kyle's scientific contributions have helped transform the diagnosis & treatment of #myeloma, and it was a
As September is #BloodCancerAwarenessMonth, we wanted to share our recent podcast on the diagnosis & management of hematologic malignancies during pregnancy ft. Daan Dierickx of @UZLeuven.🤰🩸
Learn about key factors guiding clinical decisions in pregnant patients and the
🎥 At #ESCCongress, Luuk Kieviet of @UMCU_Intl presented preliminary findings from a KOL survey evaluating heterogeneity in cardiac #amyloidosis care across Europe.
Watch the full interview here:
👉
#CardioOnc @escardio
Heterogeneity in cardiac amyloidosis care across Europe: insights from a KOL survey
Luuk Kieviet, MD, University Medical Center Utrecht, Utrecht, Netherlands, discusses preliminary findings from a key opi...
ow.ly
Fantastic conference chaired by @Daver_Leukemia and great session on menin inhibitors in which we are all excited about combination strategies and moving into frontline Tx. Thanks for inviting me to be part of this program #iwAL26
